CMPS COMPASS Pathways plc Full Business Value

This price chart for COMPASS Pathways plc (CMPS) illustrates the enterprise value dynamics, which currently stand at 1169.12. The business develops psilocybin-based pharmaceuticals, planning to independently determine therapy pricing in the future following the alignment of reimbursement rates with government agencies. The operating model relies on external contractors to conduct trials while keeping formula development in-house. Additionally, COMPASS Pathways plc (CMPS) adheres to environmental reagent disposal standards and ethical raw material sourcing.

This indicator determines the total business acquisition cost by summing market capitalization and net debt to assess the buyer's actual expenditures. The current enterprise value of COMPASS Pathways plc (CMPS) stands at 1169.12, reflecting the company's financial stability amid the diversification of psilocybin therapy clinical trials to minimize regulatory threats in the treatment of various psychiatric disorders.